See Today's Golden Star Stocks 🔥 Free for 7 Days See Today's Golden Star Stocks 🔥 Free for 7 Days
NASDAQ:CAPR

Capricor Therapeutics Stock Predictions

etoro logo Buy CAPR
*Your capital is at risk
$29.60
+0.260 (+0.89%)
At Close: Jun 23, 2026
Forecast Earnings Financials Insider Trading Signals Historical Prices Predictions News Profile
Currently predicting for Wed, 24 Jun 2026
CAPR Live board
Community Bull/Bear
Target Next close

Join the CAPR prediction battle

Create a free account to see the full board, submit your call, compare with other predictors, and build a public record.

Create free account Log in

CAPR Prediction Chart

Unlock the prediction chart

Registered users can inspect target prices, community averages, and how calls develop across recent sessions.

Create free account Log in
Forecast Desk

3-Month Forecasts For CAPR

Forecasts map a 66-session price path from approved predictors. Log in or create a free account to view forecasts and request one for this ticker.

Create free account Log in to view forecasts

CAPR Predictions History

Predictor Target Session Target Price Accuracy
Community predictor Next session USD target Record locked
Ranked predictor Previous session Bullish/Bearish Score locked

See the prediction record

Register to view community history, predictor profiles, accuracy, scores, and your own prediction trail for CAPR.

Create free account Log in
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Log in or create a free account to view and request 66-session forecasts for CAPR.
  • Price path
  • Approved predictor
  • 3-month horizon
Create Free Account Log In To View Forecasts
ABOUT CAPRICOR THERAPEUTICS
Capricor Therapeutics
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Ph...
Read Full Profile Here
GOLDEN STAR
Ticker Change Signal Date
IDYA
$28.98
18.12% Jun 12
DHI
$146.71
6.29% Jun 10
PHM
$118.49
6.02% Jun 10
EAT
$140.46
17.09% Jun 05
E
ETD
$20.67
3.19% Jun 05
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE